Slide thumbnail
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
Slide thumbnail
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
Slide thumbnail
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
Slide thumbnail
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.
RadioMedix and Viewpoint MT secure a second SBIR NCI grant for image guided therapy for metastatic melanoma
Slide thumbnail
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
Slide thumbnail
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
Radiomedix Receives Phase I SBIR Funding from the NCI for Metastatic Melanoma Theranostics
Viewpoint/Radiomedix Partner to Win SBIR Funding
Slide thumbnail
RadioMedix, Inc. Receives FDA Orphan Drug Designation for the 68Ga-DOTATATE (GalioMedix TM) for the management of the neuroendocrine tumors
Dr. Tworowska selected as 2013 U.S. IUPAC and UNSC Young Observer and recipient the Travel Award for the IUPAC Congress
[image]
Dr.Tworowska invited to present at the 2013 Biomarkers and Clinical Research Conference
RadioMedix Presented at the EANM Congress 2012

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

February 6th, 2017|Comments Off on The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

October 31st, 2016|Comments Off on RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

October 18th, 2016|Comments Off on RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.

August 23rd, 2016|Comments Off on RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.

NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.

January 21st, 2016|Comments Off on NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.

RadioMedix and Viewpoint MT secure a second SBIR NCI grant for image guided therapy for metastatic melanoma

August 17th, 2015|Comments Off on RadioMedix and Viewpoint MT secure a second SBIR NCI grant for image guided therapy for metastatic melanoma